Bristol-Myers Squibb BMY Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $10.21B-1.3% | $10.35B-9.8% | $11.46B+22.9% | $9.33B-34.9% | ||
| $464M-9.6% | $513M-37.1% | $816M+528% | $130M-95.6% | ||
| $11.41B+6.2% | $10.75B-1.6% | $10.92B+10.5% | $9.89B+5.5% | ||
| $2.69B+5.2% | $2.56B-3.9% | $2.66B+450% | $484M-46.8% | ||
| $29.39B-1.3% | $29.78B-6.3% | $31.77B+16.5% | $27.27B-18.0% | ||
| $7.54B+5.7% | $7.14B+7.4% | $6.65B+6.3% | $6.26B+3.4% | ||
| $21.75B+0.2% | $21.72B+2.6% | $21.17B+0.1% | $21.15B+3.2% | ||
| -$392M-109% | $4.24B+53.0% | $2.77B+106% | $1.34B-6.6% | ||
| $90.04B-2.8% | $92.6B-2.7% | $95.16B-1.7% | $96.82B-11.4% | ||
| $3.58B-0.7% | $3.6B+10.5% | $3.26B+7.2% | $3.04B+3.1% | ||
| $2.26B+10.5% | $2.05B-34.4% | $3.12B+1,672% | $176M+67.6% | ||
| $202M+11.6% | $181M+11.7% | $162M+19.1% | $136M-19.5% | ||
| $2.26B+10.5% | $2.05B-34.4% | $3.12B-26.9% | $4.26B-13.8% | ||
| -$324M— | $0— | —— | $942M+24.9% | ||
| $23.42B-1.5% | $23.77B+6.8% | $22.26B+1.7% | $21.89B+0.1% | ||
| $42.85B-10.0% | $47.6B+29.9% | $36.65B+4.6% | $35.06B-11.5% | ||
| $5.04B+12.8% | $4.47B-30.4% | $6.42B-2.6% | $6.59B-10.1% | ||
| $71.53B-6.1% | $76.22B+16.1% | $65.67B0.0% | $65.7B-10.4% | ||
| $292M0.0% | $292M0.0% | $292M0.0% | $292M0.0% | ||
| $46.39B+0.8% | $46.02B+0.7% | $45.68B+1.1% | $45.17B+1.8% | ||
| $16.9B+13.3% | $14.91B-48.2% | $28.77B+12.8% | $25.5B+7.1% | ||
| -$1.52B-23.1% | -$1.24B+19.9% | -$1.55B-20.7% | -$1.28B-1.0% | ||
| $43.58B-0.2% | $43.66B-0.3% | $43.77B+13.3% | $38.62B+23.5% | ||
| $18.47B+13.1% | $16.34B-44.5% | $29.43B-5.3% | $31.06B-13.6% | ||
| $90.04B-2.8% | $92.6B-2.7% | $95.16B-1.7% | $96.82B-11.4% | ||
| $464M-9.6% | $513M-37.1% | $816M+528% | $130M— | ||
| $4.61B-17.9% | $5.62B-4.9% | $5.91B+1.9% | $5.8B+19.9% | ||
| $6.47B+6.0% | $6.11B+13.7% | $5.37B+8.7% | $4.94B-10.7% | ||
| $396M+23.8% | $320M-12.1% | $364M— | $0— | ||
| $5.38B+27.0% | $4.24B+53.0% | $2.77B+106% | $1.34B-6.6% | ||
| $19.1B-18.0% | $23.31B-13.9% | $27.07B-24.5% | $35.86B-15.7% | ||
| $6.47B+6.0% | $6.11B+13.7% | $5.37B+8.7% | $4.94B-10.7% | ||
| $6.47B+6.0% | $6.11B+13.7% | $5.37B+8.7% | $4.94B-10.7% | ||
| $17.58B-3.0% | $18.13B+14.1% | $15.88B+8.9% | $14.59B+4.4% | ||
| $0— | $0— | $0— | $0— | ||
| $2.26B+10.5% | $2.05B-34.4% | $3.12B-26.9% | $4.26B-13.8% | ||
| $222M-39.8% | $369M+9.2% | $338M-84.4% | $2.17B-51.9% | ||
| $33M-37.7% | $53M-3.6% | $55M-3.5% | $57M-5.0% | ||
| 2.5K-12.5% | 2.9K-2.9% | 3K— | —— | ||
| 2.5K-12.5% | 2.9K-2.9% | 3K— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Bristol-Myers Squibb's total assets?
- Bristol-Myers Squibb (BMY) holds $86.5B in total assets, down 6.4% year over year.
- How much debt does Bristol-Myers Squibb have?
- Bristol-Myers Squibb carries $44.7B in total debt against $20.1B of shareholders' equity, a debt-to-equity ratio of 2.23.
- How much cash does Bristol-Myers Squibb have?
- Bristol-Myers Squibb holds $9.6B in cash and equivalents.
- Can Bristol-Myers Squibb cover its short-term obligations?
- Its current ratio is 1.42 — current assets exceed current liabilities.
- Where does Bristol-Myers Squibb's balance sheet data come from?
- Every line is extracted from Bristol-Myers Squibb's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
